Loading news...
The average of price targets set by Wall Street analysts indicates a potential upside of 43.4% in Privia Health (PRVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Shares of Privia Health Group, Inc. (NASDAQ: PRVA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the sixteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The
WILMINGTON, Del.--(BUSINESS WIRE)-- #AIinHealthcare--Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ: EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rat.
The mean of analysts' price targets for Privia Health (PRVA) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Privia Health Group, Inc. (PRVA) Q4 2025 Earnings Call Transcript
Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Privia Health (PRVA) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.03 per share a year ago.
All 2025 Operating and Financial Metrics At or Above High End of Guidance Ranges Full-year 2025 Net Income +59.3% from 2024 Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024 Full-year 2025 Net Cash Provided by Operating Activities of $163.4 Million , +49.5% from 2024; Year-end 2025 Cash Balance of $479.7 Million and No Debt 2026 Guidance Reflects ~20% Adjusted EBITDA Growth at Midpoint ARLINGTON, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial and operating results for the fourth quarter and full year ended December 31, 2025.
Evaluate the expected performance of Privia Health (PRVA) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Privia Health Group (NASDAQ: PRVA - Get Free Report) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $516.6090 million for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025
Privia Health Group (NASDAQ: PRVA - Get Free Report) and Azenta (NASDAQ: AZTA - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Risk and Volatility Privia Health Group has a
Butterfly Network (NYSE: BFLY - Get Free Report) and Privia Health Group (NASDAQ: PRVA - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends. Valuation and Earnings This table compares Butterfly
Pulmonx (NASDAQ: LUNG - Get Free Report) and Privia Health Group (NASDAQ: PRVA - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability. Analyst Ratings This is a breakdown of current
Privia Health Group (NASDAQ: PRVA - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership. Profitability This table compares
ARLINGTON, Va., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its fourth-quarter and twelve-month periods ended December 31, 2025 before market open on Thursday, February 26, 2026.
Three Healthcare IT stocks have surged over 20% in 2025, driven by growth in telehealth, remote monitoring and value-based care platforms.
Privia Health Group (NASDAQ: PRVA - Get Free Report) and Decision Diagnostics (OTCMKTS:DECN - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Volatility and Risk Privia Health Group has
Privia Health Group, Inc. (NASDAQ: PRVA - Get Free Report) CFO David Mountcastle sold 23,887 shares of the firm's stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $25.03, for a total transaction of $597,891.61. Following the completion of the sale, the chief financial officer owned
Precipio (NASDAQ: PRPO - Get Free Report) and Privia Health Group (NASDAQ: PRVA - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings. Risk and Volatility Precipio has a beta of
Capital Fund Management S.A. bought a new position in shares of Privia Health Group, Inc. (NASDAQ: PRVA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 28,510 shares of the company's stock, valued at approximately $656,000. Several